Back to search results

SOUL Study: Understanding Senescent Cells in Uterine Fibroids

This observational study, called the SOUL Study, is looking into the role of senescent cells (cells that have stopped dividing but remain active) in uterine fibroids (non-cancerous growths in the uterus). Researchers believe these cells might work with immune cells to create a cycle that leads to fibroid growth. The study aims to create a detailed map of these senescent cell types in fibroid and healthy uterine tissue. You may be able to join if you are a woman between 18 and 55 years old with suspected uterine fibroids, are or have been sexually active, and can understand English or Spanish. The study's current status is unclear, and it plans to enroll 150 participants.

Study design
This is an observational study with a planned enrollment of 150 women. It does not specify a phase.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is measured at 5 years, which may indicate a follow-up period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06135870

Role of Senescent Cells in Uterine Fibroid Pathogenesis (SOUL Study)

Recruiting
Not specifiedAges 18–55Observational
Johns Hopkins University
~150 participants
Updated 2025-12-11 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Develop an atlas to comprehensively quantify the rate of senescent cell (SnC) types in fibroid and myometrium tissue samples
Measured over 5 years

Conditions

Fibroid
Leiomyoma

Explore related trials

Uterine Corpus Leiomyoma

NCT06135870

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Johns Hopkins Hospital

    Baltimore, Marylandstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • James Segars, MD · PRINCIPAL_INVESTIGATOR · Johns Hopkins University

Who to contact

James Segars, MD
[email protected]
410-614-2000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subjects must be women above the age of ≥18 - ≤55 years.
Women with suspected uterine fibroids.
Subject must be or have been sexually active or have had a previous vaginal exam that used a speculum.
Subject must be able to understand, read and speak English or Spanish and subsequently, be able to understand what she is consenting to in terms of procedures and use/disclosure of protected health information.

Exclusion

Unwilling to sign the consent form or complete questionnaire.
Pregnancy.
Cancer of the uterus

What this trial measures

  • Develop an atlas to comprehensively quantify the rate of senescent cell (SnC) types in fibroid and myometrium tissue samples5 years

    Perform scRNASeq on human fibroids and control myometrium tissue and apply transfer learning algorithm for SnC identification and phenotyping to identify cell-cell communication patterns in fibroids versus control myometrial tissue using Domino to validate computationally predicted senescent cell types. The computationally predicted immune phenotypes will be validated with flow cytometry.